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Abstract: Enterotoxigenic Escherichia coli (ETEC) strains are a major cause of diarrhea in 
humans  and  animals.  Heat-stable  (STa)  and  heat-labile  (LT)  enterotoxins  produced  by 
ETEC disrupt fluid homeostasis in host small intestinal epithelial cells and cause fluid and 
electrolyte hyper-secretion that leads to diarrhea. ETEC strains producing STa or LT are 
sufficiently virulent to cause diarrhea, therefore STa and LT antigens must be included in 
ETEC  vaccines.  However,  potent  toxicity  and  poor  immunogenicity  (of  STa)  prevent  
them from being directly applied as vaccine components. While LT toxoids, especially 
LT(R192G), being used in vaccine development, STa toxoids have not been included. A 
recent study (IAI, 78:316-325) demonstrated porcine-type STa toxoids [pSTa(P12F) and 
pSTa(A13Q)] elicited protective anti-STa antibodies after being fused to a porcine-type LT 
toxoid [pLT(R192G)]. In this study, we substituted the 8th, 9th, 16th, or the 17th amino 
acid of a human-type STa (hSTa) and generated 28 modified STa peptides. We tested each 
STa peptide for toxicity and structure integrity, and found nearly all modified STa proteins 
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showed structure alteration and toxicity reduction. Based on structure similarity and toxic 
activity,  three  modified  STa  peptides:  STa(E8A),  STa(T16Q)  and  STa(G17S),  were 
selected to construct LT192-STa-toxoid fusions. Constructed fusions were used to immunize 
mice, and immunized mice developed anti-STa antibodies. Results from this study provide 
useful information in developing toxoid vaccines against ETEC diarrhea. 
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1. Introduction 
A recent systematic survey indicated that diarrhea kills up to 2 million children under the age of 
five, more than AIDS, malaria and measles combined [1,2]. Enterotoxigenic Escherichia coli (ETEC) 
strains that colonize host small intestines and produce one or two enterotoxins are the major bacterial 
cause of children’s diarrhea, and are responsible for approximately 200 million episodes of diarrhea 
and  380,000  deaths  annually  [3].  In  addition,  ETEC  strains  are  also  the  most  common  cause  of 
travellers’  diarrhea  [4,5].  Although  experimental  vaccines  currently  under  development  show 
promising, no broadly effective vaccines are available to protect humans and animals against ETEC 
diarrhea. The key virulence factors of ETEC in diarrhea are colonization factors and enterotoxins [6–12]. 
Colonization factors mediate initial attachment of ETEC bacteria to host small intestinal enterocytes 
and  subsequent colonization.  Enterotoxins  known as  heat-stable (STa)  and heat-labile (LT) toxins 
disrupt fluid homeostasis and cause fluid and electrolyte hyper-secretion through activation of adenyl 
cyclase  (by  LT)  or  guanylate  cyclase  (by  STa)  in  small  intestinal  epithelial  cells  that  leads  to  
diarrhea [13,14]. 
LT and STa toxins, in addition to colonization factors are proven the virulence determinants in 
ETEC diarrhea. LT is a typical 1A:5B toxin that consists of one enzymatic A subunit (25.5 KDa) and 
five  identical  GM1-binding  B  subunits  (12  KDa),  and  is  strongly  immunogenic.  In  contrast,  STa 
associated with human diarrhea (hSTa; STa used in following context is referred as hSTa) is a small 
peptide of only 19 amino acids (2 KDa) and is poorly immunogenic [10]. Epidemiological and clinical 
studies showed that one half of human diarrheal cases associated with ETEC are caused by strains that 
produce STa toxin only, a quarter express LT only, and another quarter produce both toxins [15,16]. 
Human volunteers and animal challenge studies demonstrated that an enterotoxigenic E. coli strain 
expressing either STa or LT toxin is sufficiently virulent to cause diarrhea [10–12,17]. Therefore, both 
STa and LT toxins must be targeted in vaccine development against ETEC diarrhea [18–21]. Indeed, 
experimental vaccine studies indicated that anti-LT immunity alone is not sufficiently effective in 
protection against ETEC. Vaccine candidates carrying LT antigens provided protection against only 
LT-producing ETEC strains, but not against ETEC strains expressing STa toxin [22,23]. It becomes 
commonly  acknowledged  that  anti-STa  immunity  must  also  be  induced  by  vaccines  for  effective 
protection against ETEC diarrhea.  
The potent toxicity of LT and STa, however, must be attenuated, and the poor immunogenicity of 
STa must be enhanced before LT and STa can be used as safe and effective vaccine antigens. LT 
toxoids, especially LT(R192G) that has the Arg
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but LT immunogenicity (and adjuvanticity) maintained and were used as antigens in ETEC vaccine 
development [24–26]. This LT(R192G) has also been used as an adjuvant to enhance immunogenicity 
of otherwise poorly immunogenic antigens [27–32]. In contrast, although early studies demonstrated a 
few modified STa peptides including STa12, STa13 and STa14 showed toxicity reduction [33,34], STa 
toxoids have not been included in ETEC vaccine development until recently [35,36]. Recent studies 
showed  that  porcine-type  STa  toxoids,  pSTa(P12F)  and  pSTa(A13Q)  which  are  the  analogues  of 
human-type STa13 and STa14, had anti-STa immunogenicity enhanced and elicited protective anti-STa 
antibodies after being genetically fused to toxoid LT(R192G) [35] or E. coli K88ac fimbriae [36]. 
Candidacy of other STa toxoids in vaccine application, however, has not been evaluated. In addition, 
studies showed that different STa toxoids exhibited differences in toxicity reduction [34] and likely 
structure alteration [35]. Further studies to examine additional modified STa peptides for correlation 
between anti-STa immunogenicity (when are carried by a carrier protein) and toxicity reduction or 
structure  integrity  will  provide  instructive  information  to  select  STa  toxoids  in  developing  ETEC 
toxoid vaccines. 
In this study, we generated various modified STa peptides by substituting the 8th, 9th, 16th and 
17th amino acids of STa toxin. The 8th, 9th, 16th and 17th residues located inside the STa toxic 
domain which consists of a peptide from Cys
6 to Cys
18 and constitutes the minimal structure for fully 
biological activity of the STa toxin [37]. As the 6 cysteines that form three disulfide bonds, Cys
6 to 
Cys
11,  Cys
7  to  Cys
15,  and  Cys
10  to  Cys
18,  are  essential  to  maintain  the  STa  three-dimensional 
conformation, and STa12, STa13, and STa14 had already been characterized, the 8th, 9th, 16th and 17th 
are the only residues left inside the toxicity domain to be studied for their role(s) in STa enterotoxicity 
and  structure  integrity.  We  substituted  each  of  these  four  amino  acids  with  a  residue  of  different 
characterization, such as molecular weight, accessible surface area and polarity, and examined each 
modified STa protein for changes in structure and toxicity. Furthermore, we selected three modified 
STa  peptides  based  on  their  structure  similarity  and  toxic  activity  to  construct  LTR192G-STa-toxoid 
fusions and examined the fusions for anti-STa antigenicity. 
2. Materials and Methods 
2.1. Bacterial Strains and Plasmids 
ETEC strain E. coli H10407 (O78:H11) was used to isolate the STa gene (estA), and E. coli BL21 
(GE  Healthcare,  Piscataway,  NJ,  USA)  was  used  as  the  host  strain  in  this  study.  Vector  pUC19 
(Promega, Madison, WI, USA) was used to clone and express the wildtype and mutated STa genes, 
and expression vector pET28α (Invitrogen, Carlsbad, CA, USA) was used to express LT and STa 
toxoid fusions. BL21 strain expressing native STa was used as the positive control, whereas BL21 with 
vector pUC19 as the negative control. All strains were cultured in LB medium or 4AA minimum 
medium supplemented with kanamycin (30 µ g/mL) or ampicillin (50 µg/mL) accordingly (Table 1). 
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Table 1. Escherichia coli strains and plasmids used in this study. 
Strains  Relevant properties  Plasmid  Reference 
H10407  ETEC prototype strain  LT
+STa
+  ATCC #35401 
BL21  E. coli B F
−, ompT, hsdS (rB
−, mB
−), gal, dcm.  GE Healthcare 
8964  LTR192G-STaE8A construct, BL21/pLTR192G-STaE8A  pLTR192G-STaE8A/pET28α  this study  
8968  LTR192G-STaT16Q construct, BL21/pLTR192G-STaT16Q  pLTR192G-STaT16Q/pET28α  this study  
8971  LTR192G-STa construct, BL21/pLTR192G-STa  pLTR192G-STa/pET28α  this study  
8975  LTR192G-STaG17S construct, BL21/pLTR192G-STaG17S  pLTR192G-STaG17S/pET28α  this study  
8836  STa recombinant, BL21/pSTa  pSTa/pUC19   this study 
8930  negative control, BL21  pUC19  this study 
2.2. Cloning and Mutation of estA Gene 
The STa gene (estA) was PCR amplified from genomic DNA of  ETEC strain H10407 (ATCC 
#35401)  with  designed  primers  hSTapUCHindIII-F  (5'-gcgcaaagcttctgattttgat-3';  underlined  is  a 
HindIII site) and hSTapUCBamHI-R (5'-agccacggcggatccaaatataaaggg-3'; underlined is a BamHI site) 
in a PCR as described previously [35]. PCR amplified products were separated in 1.5% agarose gel 
(FMC  Bioproducts,  Rockland,  MA,  USA)  and  extracted  using  a  QIAquick  gel  extraction  kit 
(QIAGEN,  Valencia,  CA,  USA).  Purified  PCR  products  and  plasmid  pUC19  were  digested  with 
HindIII and BamHI restriction enzymes (New England Biolab, Ipswitch, MA, USA). Digested estA 
gene products and vectors were gel electrophoresed and purified, and ligated with T4 DNA Ligase 
(New England BioLab). Two microliters of ligation products were used to transform E. coli BL21 
competent cells under a standard electroporation procedure [38]. Antibiotic resistant colonies were PCR 
screened first, followed by DNA sequencing to ensure that the cloned estA gene stayed in the correct 
reading frame. 
To substitute the 8
th, 9
th, 16
th and the 17
th amino acids of the STa toxin, we designed specific PCR 
primers to mutate nucleotides encoding these four residues (supplementary Table 1). A list of codons 
and substitutions were illustrated in Figure 1. We designed primers to substitute the Glu
8 with Pro, 
Ala, Phe, Ser, Gly, Arg, Lys or Gln; the Leu
9 with Val, Ile, Gln, Lys, Arg, Gly or Ser; the Thr
16 with 
Ala, Phe, Gln, Lys, Arg, Gly or Ser; and the Gly
17 with Ala, Lys, Gln, Arg, Ser or Phe (Figure 1). The 
eltAB  genes coding  LT  toxin were PCR amplified from  genomic DNA of H10407  and cloned in 
pUC19 vector, and were mutated with LT192-F and LT192-R PCR primers [26], for toxoid LT(R192G). 
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Figure 1. Illustration of a mature STa toxin peptide and substitutions. Amino acid residues 
in the red-colored dashed box are of STa toxicity domain, and three disulfide bonds are 
indicated in blue-colored solid lines. Boxes in green-colored solid line indicated amino 
acid residues used in substitution. 
 
2.3. STa Competitive ELISA to Detect STa Proteins Expressed by the Recombinant and Mutant Strains 
Reactivity to anti-native STa antiserum (D. Robertson laboratory) was measured to assess structure 
integrity among the modified STa peptides. Culture growth of the STa recombinant and mutant strains 
was used in STa competitive ELISA as described previously [35,39]. Briefly, each strain was cultured 
in LB overnight, and grown culture was measured with optical density (OD). An equivalent amount of 
cells from each strain was sub-cultured in 4 AA medium at a start OD value of 0.05. After 8 h growth, 
culture  was  measured  for  OD  again.  Supernatant  from  an  equivalent  amount  of  cells  was  used  
in ELISA. 
STa ovalbumin-conjugates (1.25 ng; D. Robertson laboratory) were coated at each well in a STa 
ELISA plate overnight at 37 ° C. The coated plate was blocked with 2.5% casein blocking buffer (2.5% 
casein in 0.3 N NaOH, pH 7.0) at 37 ° C for 1 h. Seventy-five microliters of culture supernatant from 
each  strain  (in  triplicate)  and  75  µL  of  anti-native  STa  rabbit  antiserum  (1:10,000  dilution;  
D. Robertson laboratory) were mixed and added to each well, followed by an incubation at 37 ° C for  
2 h on a shaker (180 rpm). After three washes, plates were blotted to dry, incubated with horseradish 
peroxidase  (HRP)-conjugated  goat  anti-rabbit  immunoglobulin  (IgG,  1:10,000  dilution)  (Sigma,  
St. Louis, MO, USA) at 37 ° C for 1 h. OD was measured at a wavelength of 405 nm after 20 min of 
incubation in peroxidase substrate (KPL, Gaithersburg, MA, USA). 
Reactivity to anti-STa antiserum from each mutated STa peptide was measured and compared to 
that of the recombinant STa to assess protein structure similarity, with an assumption that a modified 
STa peptide will have similar reactivity to anti-STa antiserum as the recombinant STa peptide if this 
modified STa peptide maintains similar structure of the recombinant STa. With the reactivity of the 
recombinant STa peptide to anti-STa antiserum was set as 100% and that of the negative control to 
antiserum as 0%, reactivity of each modified STa peptide to the anti-STa antiserum was calculated and 
converted to structural similarity to the native STa. 
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2.4. Intracellular Cyclic GMP ELISA to Detect Toxicity of STa Peptides 
Toxicity of the recombinant and mutated STa peptides was determined for stimulating intracellular 
cyclic GMP in T-84 cells (ATCC #CCL-248) with a direct cyclic GMP enzyme immunoassay kit 
(Correlate
TM EIA, Assay Designs, MI, USA), as described previously [35]. Briefly, 1 ×  10
5 T-84 cells 
were seeded and cultured in the Dulbecco’s modified Eagle medium (DMEM/F12; GIBCO/Invitrogen, 
Grand  Island,  NY,  USA).  After  removal  of  culture  medium,  75  µL  overnight-grown  supernatant  
(in 4AA medium, of equivalent amount of cells) from each strain (in duplicate) was added to each well 
of a 24-well plate, and incubated for 2 h. Cells were lysed with 100 µL 0.1 M HCl and then were 
neutralized with 0.1 M NaOH. One hundred microliter lyses supernatant was mixed with the reagents 
(conjugates and antibodies) supplied with the kit, and was added to each well of the supplied EIA 
plate. After incubation on a shaker (500 rpm) for 2 h at room temperature, plates were washed and 
blotting dried. Reactivity with supplied pNpp substrate solution (OD value) was measured at 405 nm 
after 20 min development. 
2.5. Porcine Ligated Gut Loop Assays to Detect Biological Activity of Expressed STa Proteins 
STa proteins expressed by the recombinant and mutant strains were also examined for biological 
activity in porcine ligated loop assays as described previously [12,17]. Three 7-day old piglets were 
deprived of food overnight (with supply of water ad libitum), and were surgically prepared for 24, 24, 
and  20  loops  from  ileum  and  lower  jejunum  segments.  Twenty-eight  toxoid  mutant  strains  were 
randomly divided into 3 groups (10, 10, and 8), and the recombinant strain and the negative control 
were added to each group. Two ×  10
9 CFUs of overnight-grown culture from each strain were injected 
into each ligated loop (in duplicate; 1–10, +, −; 1–10, +, −). After 8 h post-inoculation, the length of 
each  loop  (cm)  and  amount  of  fluid  accumulated  in  each  loop  (g)  were  measured.  The  ratio  of 
accumulated  fluid to the loop length (g/cm) was calculated to assess enterotoxic activity  for each 
expressed STa protein. A ratio of greater than 0.1 is typically considered as positive of enterotoxicity. 
2.6. Construction and Expression of LTR192G-STaE8A, LTR192G-STaT16Q, LTR192G-STaG17S, and  
LTR192G-STa Fusions 
Three modified STa  peptides,  STa(E8A),  STa(T16Q) and STa(G17S), were selected for fusion 
construction. Each STa peptide was genetically fused to the LT(R192G) through an L-linker peptide [24] 
in a three-step PCR method described previously [26,35]. In addition, the native STa was also included 
in fusion construction. Each fusion gene was cloned into vector pET28α and expressed in E. coli BL21 
strain as 6xHis-tagged fusion proteins. As the stop codon of LT(R192G), and the transmembrane signal 
peptides of the LTR(192G) and each STa peptide were removed, each fusion was constructed as one 
open reading frame and thus expressed as a single protein.  
Total proteins extracted from each fusion strain were used to examine fusion protein expression in a 
standard Western blot with anti-CT (Sigma) and anti-STa antiserum (D. Robertson laboratory). Fusion 
strains were grown in LB medium supplemented with kanamycin (30 µg/mL) at 37 ° C overnight. 
Upon the OD600 value reached to 0.5, culture growth was induced by adding 1 mM isopropyl-β-D-
thiogalactopyranoside (IPTG) and cultured continually for 4 h. Total proteins were extracted using Toxins 2011, 3  1152 
 
 
bacterial protein extraction reagent by following the manufacture’s protocol (B-PER, in phosphate 
buffer; Pierce, Rockford, IL, USA). Thirty microliters of total protein extracts from each fusion strain 
were used in a standard sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and 
immunoblot assay [38]. Transferred membrane blots were blocked with 2% fat-free milk overnight  
at  4  ° C,  incubated  with  rabbit  anti-CT  (1:3000;  Sigma)  and  anti-STa  serum  (1:5000;  Robertson 
laboratory), respectively. Fusion proteins on the blots recognized by IRDye conjugated goat anti-rabbit 
IgG  (1:5000;  LI-COR,  Lincoln,  NE,  USA)  were  visualized  with  a  LI-COR  Odyssey  Infared  Gel 
Imaging  system  (LI-COR).  In  addition,  fusion  proteins  were  also  examined  in  SDS-PAGE  with 
standard Coomassie blue staining. 
2.7. Extraction and Refolding of Fusion Proteins, and Mouse Immunization 
Fusion proteins extracted in the format of inclusion bodies were denatured and refolded before 
being  used  in  mouse  immunization.  Proteins  extracted  as  inclusion  bodies  were  refolded  using  a 
protein refolding kit with buffer #5 and #9 according to the manufacture’s instruction (Pierce). Three 
female adult BALB/c mice (Harlan, Indianapolis, IN, USA) per group were immunized intraperitoneally 
(IP) with each refolded fusion protein. One hundred microgram of fusion proteins, in an equal volume 
of  Freud’s  incomplete  adjuvant  (Sigma),  was  injected  to  each  mouse  in  the  group.  One  booster 
injection was followed two weeks later. One group of 3 mice without injection was used as the control 
group. All mice were sacrificed two weeks after the booster injection. Blood samples were collected 
before and 14 days after each injection, and collected serum samples were stored at −80 ° C until use. 
Anti-STa antibodies were titrated from serum samples in STa ELISA as described previously [35,36]. 
Briefly,  1.25  ng  STa-ovalbumin  conjugates  was  coated  in  each  well  of  a  96-well  plate  at  37° C 
overnight. Each well was blocked with 2.5% casein blocking buffer, and  then incubated with  the 
mouse serum samples (in a binary dilution started at 1:40; in triplicate). Serum samples from the 
control mice were also included. HRP-conjugated goat anti-mouse IgG (1:4000; Sigma) was used as 
the secondary antibodies. The cutoff OD values in ELISA were defined as the A405 of the background 
plus 0.4. The dilution that gave OD values above the cutoff was calculated for antibody titers which 
were expressed at the log10 scale. 
All animal studies complied with the Animal Welfare Act, followed the Guide for the Care and Use 
of  Laboratory  Animals  [40],  and  were  under  the  supervision  of  South  Dakota  State  University’s 
Institutional Animal Care and Use committee. 
2.8. Statistical Analysis 
Data were analyzed using the mixed procedure (SAS for windows, version 8; SAS Institute, Cary, 
NC, USA), and Student’s t-test was used to compare different treatment groups. Data were presented 
as means and standard deviations. Calculated p values of <0.05 were regarded as significant when 
treatment groups were compared at two-tailed distribution and two-sample equal variance. 
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3. Results 
Twenty-eight mutant strains were constructed in this study, and STa proteins expressed from each 
mutant strain was examined for toxic activity and structure integrity (Table 2). Three out 28 modified 
STa peptides, STa(E8A), STa(T16Q) and STa(G17S) which showed less changes at structure, toxic 
activity, or both, were selected for constructing LT192-STa-toxoid fusions. Each fusion was used in mouse 
immunization for assessing the influence of STa structure and/or toxicity in anti-STa antigenicity.  
Table 2. Structure alteration and toxicity of STa expressed by mutant strains. Supernatant 
of overnight growth (in 4 AA medium) from an equal amount of cells for each strain was 
used in STa competitive ELISA and cGMP ELISA. Reactivity of modified STa peptides  
to  anti-STa  serum  was  expressed  as  protein  structure  similarity  by  referring  to  the 
recombinant STa. Crude overnight culture growth of each mutant strain, the recombinant 
strain, and the negative control strain was used in porcine ligated gut loop assay. 
STa Toxoid 
Strain 
Structure Similarity Based 
on STa competitive ELISA 
cGMP ELISA (pmole/mL) 
in T-84 Cells 
Ligated Gut Loop Assay 
(g/cm) 
8845 (STaE8P)  65.1 ±  4.5  0.37 ±  0.15  0.08 ±  0.00 
8847 (STaE8A)  50.3 ±  3.5  9.4 ±  1.63  0.50 ±  1.03 
8849 (STaE8F)  27.1 ±  15.5  0.11 ±  0.01  0 
8851 (STaE8S)  15.0 ±  3.7  0.08 ±  0  0 
8852 (STaE8G)  0.7 ±  1.0  0.08 ±  0  0 
8854 (STaE8R)  33.6 ±  0.1  0.12 ±  0.01  0 
8856 (STaE8K)  40.3 ±  7.2  0.16 ±  0.03  0 
8858 (STaE8Q)  53.8 ±  0.2  5.1 ±  0.141  0.37 ±  0.34 
8860 (STaL9V)  48.0 ±  10.1  0.09 ±  0.07  0 
8861 (STaL9I)  54.9 ±  1.7  0.55 ±  0.03  0.09 ±  0.12 
8862 (STaL9Q)  0 ±  0  0.09 ±  0.11  0  
8863 (STaL9K)  68.8 ±  2.7  0.12 ±  0.01  0.01 
8865 (STaL9R)  9.2 ±  9.7  0.10 ±  0.03  0  
8867 (STaL9G)  21.9 ±  3.9  0.11 ±  0.01  0 
8869 (STaL9S)  31.0 ±  3.9  0.09 ±  0.01  0 
8870 (STaT16A)  77.3 ±  2.7  0.50 ±  0.04  0  
8872 (STaT16P)  87.3 ±  0.8  0.39 ±  0.01  0 
8874 (STaT16Q)  88.6 ±  5.2  0.19 ±  0.07  0 
8876 (STaT16K)  68.9 ±  0.4  0.10 ±  0.01  0.03 ±  0.01 
8878 (STaT16R)  36.6 ±  10.5  0.12 ±  0.00  0.02 ±  0.01 
8880 (STaT16G)  51.4 ± 5.2  0.18 ±  0.01  0.04 ±  0.04 
8882 (STaT16S)  68.7 ±  7.8  0.44 ±  0.02  0.17 ±  0.08 
8884 (STaG17A)  78.8 ±  6.4  0.31 ±  0.01  0.05 ±  0.05 
8886 (STaG17K)  83.8 ±  4.0  0.52 ±  0.06  0.07 ±  0.07 
8888 (STaG17Q)  59.6 ±  12.0  0.17 ±  0.01  0.05 ±  0.05 
8890 (STaG17R)  46.1 ±  13.2  0.22 ±  0.13  0.02 
8892 (STaG17S)  93.4 ±  2.7  17 ±  1.41  0.33 ±  0.08 
8894 (STaG17F)  91.6 ±  2.3  1.33 ±  0.67  0.05 ±  0.02 
8836 (native STa)  100%  >50  0.58 ±  0.01 
8930 (-)  0%  0.08 ±  0  0.01 
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3.1. STa Proteins Expressed from Mutant Strains Showed Structure Alteration  
The STa genes in the mutant strains and the recombinant strain were verified with DNA sequencing, 
and expressed STa peptides were examined in STa competitive ELISA with STa-ovalbumin conjugates 
as  the  competitive antigens  and  anti-native  STa antiserum as the primary  antibodies. ELISA data 
showed modified STa peptides had a wide range of structure alteration. After being substituted with a 
Gly at the Glu
8 or a Gln at the Leu
9, resultant STa proteins, STa(E8G) and STa(L9Q), no longer 
reacted to anti-STa serum. That indicated these two modified STa peptides had structure changed 
significantly. In contrast, the STa(T16P) (87.3 ±  0.8), STa(T16Q) (88.6 ±  5.2), STa(G17F) (91.6 ±  2.3) 
and STa(G17S) (93.4 ±  2.7) maintained a similar structure as the natural STa (Table 2). Although 
modified STa peptides showed a wide variation, ranging from 0% to 93.4%, regarding reactivity to 
anti-STa serum, STa derivatives with mutation at its Glu
8 or Leu
9 residue displayed greater structure 
alteration. The mean reactivity to anti-STa serum for the STa proteins with substitution at the 8
th and 
9
th  residues  was  35.7%  and  33.4%,  respectively.  In  contrast,  substitution  at  the  STa16  and  STa17 
residues were less sensitive to structure alteration, as STa16 and STa17 derivative STa proteins showed 
mean reactivity (to anti-STa antiserum) of 68.4% and 75.6%, respectively. 
3.2. STa Proteins Expressed from Mutant Strains Showed Toxicity Reduction 
STa proteins expressed from all mutant strains showed toxicity reduction. Indeed, STa proteins 
expressed by most mutant strains showed little or no toxic activity. Only STa(E8A), STa(E8Q), and 
STa(G17S) showed toxic activity as they stimulated an increase of intracellular cGMP level in T-84 
cells. These three mutant strains also had toxic biological activity detected in porcine ligated gut loop 
assay. Fluid accumulated in the loops incubated with mutant strains expressing STa(E8A), STa(E8Q), 
and STa(G17S) was measure at 0.50 ±  1.03, 0.37 ±  0.34, and 0.33 ±  0.08 (g/cm), respectively. In 
addition, the mutant strain expressing STa(T16S) had a positive fluid accumulation (0.17 ±  0.08 g/cm) 
in ligated gut loops (Table 2). 
3.3. STa(E8A), STa(T16Q) and STa(G17S) Exhibited Differences in Anti-STa Antigenicity When Were 
Fused to LT(R192G) 
Three  STa  proteins  that  retained  STa  structure  or  toxic  activity  were  selected  to  be  fused  
to  LT(R192G)  for  assessing  anti-STa  immunogenicity.  The  STa(E8A)  which  showed  toxicity  
(9.4 ±  1.63 pmole/mL cGMP, 0.50 ±  1.03 g/cm fluid accumulation) but had structure greatly altered 
(50.3%), STa(T16Q) that showed similar structure to native STa (88.6%) but had toxicity diminished, 
and STa(G17S) that retained STa structure (93.4%) and much of the toxicity (17 ±  1.4 pmole/mL,  
0.33 ±  0.08 g/cm) were individually fused to the LT(R192G), and each fusion protein was used in 
mouse immunization study. In addition, the wildtype STa was also fused to LT(R192G). All fusion 
proteins  were  expressed  as  inclusion  bodies  (Figure  2A)  which  were  extracted  under  denatured 
condition, but were refolded for natural formation and were verified with anti-CT (Figure 2B) and  
anti-STa antiserum (Figure 2C). 
   Toxins 2011, 3  1155 
 
 
Figure 2. Detection of expressed fusion proteins. Panel A: Total proteins extracted from 
inclusion body portion were visualized with Coomassie blue staining. The top and bottom 
purple markers are 75 and 25 KDa, and the two blue markers inside the purple markers are 
50 and 37 KDa. Panel B: detection of refolded fusion proteins by anti-CT antiserum. Panel 
C: detection of refolded fusion proteins by anti-STa antiserum. The two markers in panel B 
and  C  are  50  and  37  KDa.  Lane  1:  LTR192G-STaE8A;  lane  2:  LTR192G-STaT16Q;  lane  3: 
LTR192G-STa; lane 4: LTR192G-STaG17S.  
 
Antibody  titration  from  serum  samples  showed  that  mice  immunized  with  the  fusion  antigens 
developed anti-STa antibodies. Anti-STa IgG titers (in log10) in serum samples of mice immunized 
with  LTR192G-STaE8A,  LTR192G-STaT16Q,  and  LTR192G-STaG17S  were  1.64  ±   0.04,  1.70  ±   0.07,  and  
1.65  ±   0.07,  respectively.  Anti-STa  IgG  was  also  detected  in  mice  immunized  with  LTR192G-STa  
(1.68 ±  0.04). In contrast, no antibodies were detected in the control mice, even when serum samples at 
a 1:10 dilution were used (Figure 3). 
Statistical  analyses  suggested  there  were  no  significant  differences  at  anti-STa  IgG  antibodies 
among mice immunized with different fusion antigens. However, anti-STa IgG titers detected in mice 
immunized with LTR192G-STaT16Q and LTR192G-STaG17S, of which the carried STa had less structure 
alteration,  were  closer  to  that  of  the  group  immunized  with  LTR192G-STa  (p  =  0.53,  p  =  0.52). 
Comparatively,  anti-STa  IgG  antibody  titers  in  the  group  immunized  with  LTR192G-STaE8A  fusion 
antigen  was  relatively  more different  than  those  of the  LTR192G-STa  immunized group (p =  0.20) 
(Figure 3). 
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Figure 3. Anti-STa IgG antibody titration from serum samples of mice immunized with 
LTR192G-STaE8A,  LTR192G-STaT16Q,  LTR192G-STa  and  LTR192G-STaG17S  fusion  proteins. 
Serum samples from immunized mice (1:40 in dilution) and the control unimmunized mice 
(1:10 in dilution) were used to titrate anti-STa IgG in a STa ELISA. 1.25 ng STa-ovalbumin 
conjugates coated at each well as the antigen, and HRP-conjugated goat anti-mouse IgG 
(1:4000)  was  used  as  the  secondary  antibodies.  Boxes  and  error  bars  are  means  and 
standard deviation.  
 
4. Discussion 
As one of the virulence determinants in ETEC-associated diarrhea, STa needs to be included in 
ETEC vaccine development. Since STa is toxic and also poorly immunogenic, we need not only to 
attenuate its potent toxicity but also to facilitate its immunogenicity before we can include STa as a 
vaccine component [21,35]. STa immunogenicity can be enhanced as an early study showed the native 
STa became immunogenic when was chemically cross-linked or genetically fused to a high immunogenic 
carrier protein [21]. However, STa used in these compounds retains toxicity [18,24,41]. The toxicity 
issue was solved when shorter STa peptides or STa with disulfide bonds disrupted were used for 
crosslink or genetic fusion. However, resultant compounds failed in inducing neutralizing anti-STa 
antibodies. Thus, these STa analogues exhibited little value in ETEC vaccine application [42,43]. On 
the other hand, several non- or low-toxic LT analogues are immunogenic and show ability to induce Toxins 2011, 3  1157 
 
 
protective anti-LT immunity [24,25,44–46]. But anti-LT immunity alone is not sufficient to protect 
against ETEC [22,23]. Only vaccines also inducing protective anti-STa immunity could effectively 
protect against ETEC diarrhea [18,19]. Thus, to identify STa molecules that have low or no toxicity 
but potentially induce neutralizing anti-STa antibodies, when are cross-linked or fused to a carrier 
protein, becomes a priority in ETEC vaccine development. 
The Asn
12, Pro
13 and Ala
14 of STa were extensively studied for their significance in toxic activity. 
STa  had  toxicity  reduced  or  diminished  after  its  Asn
12,  Pro
13  or  Ala
14  residue  being  substituted 
selectively with several different amino acid residues [34]. It was demonstrated that STa showed little 
or limited toxicity reduction when the Asn
12 was replaced by a Val or an Ala, or the Pro
13 by a Val or 
an Ala, but had a thousand or ten thousand folds reduction in toxicity when the Asn
12 or Ala
14 was 
substituted with an Arg or a Lys residue [34]. It was also revealed STa showed significant variance in 
toxicity reduction when substitutions occurred at different residues. For an example, STa had toxicity 
greatly reduced when the Ala
14 residue was substituted. Data from the current study showed that STa 
toxicity reduced when the Glu
8, Leu
9 Thr
16, or the Gly
17 was substituted, and that toxicity reduction 
varied when either residue was replaced by a different amino acid residue. When the Glu
8 was replaced 
by a Phe, Pro, Ser, Gly, Arg or a Lys, STa lost all or nearly all toxic activity. But STa retained much of 
the toxicity when the same Glu
8 was substituted by an Ala or a Gln residue, based on the data form 
porcine  ligated  gut  loop  assay.  It  could  suggest  that  the  outcome  of  toxicity  reduction  may  be 
associated with basic chemical characteristics of the residues, or its hydrophobic interaction with GG-
C [47]. However, this observation is based on only a few substitutions, future systematic studies will 
be needed for better assessment of any association between basic chemical characters of substitutes 
and STa toxicity reduction. There is one report that suggested the Gly
17 resides the inner surface, and 
with the backbone atoms this Gly
17 is involved in a side-by-side hydrogen-bonding network (47). 
Therefore, substitution of Gly
17 could results in significant changes in STa peptide structure. However, 
4 out 6 substitutions {STa(G17S), STa(G17F), STa(G17K), and STa(G17A)} did not cause significant 
structural alteration in STa as they were well recognized by anti-STa serum. One possible explanation 
is that we measured structure similarity based on reactivity of STa peptides to the anti-native STa 
antiserum, and substitutions of Gly
17 with some amino acid residues may not always necessary result 
in collapse of the STa topology, thus these STa analogues can still be recognized by the anti-STa 
antiserum.  Clearly,  more  studies  will  be  needed  to  further  characterize  this  Gly
17  residue  for 
significance in STa structure and biological function. 
Generally, substitutions of a single amino acid residue could significantly affect a small molecule, 
such as STa, in structure and biological activity. STa toxin is a peptide of 19 amino acids (18 amino 
acids in porcine-type STa) including six cysteines forming three disulfide bonds. Thus any changes 
including  a  substitution  of  a  single  amino  acid  could  disrupt  the  STa  structure  and  function. 
Maintenance of the STa structure, especially the epitope topology in fusions or conjugates is believed 
to be important in eliciting neutralizing anti-STa antibodies (communication with Dr. John Clements). 
A couple of published papers confirmed that the three disulfide bonds: Cys
6 to Cys
11, Cys
7 to Cys
15, or
 
Cys
10 to Cys
18, are essential for STa to maintain its structure and function [48,49]. Therefore, we did 
not target these cysteine residues for substitution. In this study, we assessed structure integrity of the 
modified STa peptides by their reactivity to anti-STa antiserum (anti-native STa antiserum) and found 
a wide range of variation in structure alteration among these STa analogues. Peptides STa(L9Q) and Toxins 2011, 3  1158 
 
 
STa(E8G) showed no or little similarity to the native STa in structure, most likely due to that the Leu
9 
cannot tolerate amino acid substitution without a dramatic drop of STa efficiency [50]. Additionally, 
both Glu
8 and Leu
9 with Cys-Cys adopt a confirmation that tightly interacts with the hydrophobic 
region of GC-C to achieve maximum potency [51]. That suggests STa(L9Q) and STa(E8G) have the 
structure or epitope topology changed so substantially that they are no longer recognizable by the  
anti-STa  serum.  Even  if  these  two  proteins  were  strongly  antigenic,  antibodies  elicited  by  these 
proteins  likely  would  not  neutralize  native  STa  toxin.  On  the  other  hand,  other  STa  analogues 
including STa(G17S), STa(G17F), STa(T16Q), STa(T16P) and STa(G17K) showed similar reactivity 
to anti-STa serum as the recombinant STa. That suggests these STa molecules retained much of the 
STa native structure or epitope topology. If they become antigenic after being fused or conjugated, the 
elicited antibodies likely will neutralize STa toxin. While most STa peptides generated in this study 
showed toxicity reduced or abolished, three peptides STa(E8A), STa(E8Q) and STa(G17S) retained 
some STa toxicity as each stimulated an increase of cGMP in T-84 cells and also fluid accumulation in 
ligated porcine gut loops. Differently, toxicity in peptide STa(T16S) was detected only in porcine 
ligated loop assay but not in cGMP ELISA. However, the toxicity detected in the gut loop assay,  
0.17 ±  0.08 g/cm, is relatively lower compared to the other three peptides. That may indicate that 
STa(T16S) is less toxic and further studies may be needed to characterize this peptide. 
The primary goal of this study is to identify STa analogues that retain structure similar to native 
STa but show no or low toxicity to be used for constructing LT and STa toxoid fusions in ETEC 
vaccine development. Because of its small size, we expected difficulties to find STa proteins with 
minimum structure alteration but great toxicity reduction. While most of the modified STa peptides 
generated in the current study showed changed in both structure and toxicity, a few apparently had 
structure greatly altered but toxic activity retained {STa(E8A), STa(E8Q)}, or had toxicity lost but 
with minimum protein structure changed {STa(T16P), STa(T16Q), STa(G17K), STa(G17F)}. Only 
STa(G17S), however, retained much of the toxicity and the native structure, as it showed over 93% of 
similarity  in  reactivity  to  anti-STa  antiserum  and  nearly  half  of  the  toxic  activity  measured  in 
stimulation of the cGMP level or fluid accumulation in ligated gut loop. To examine whether structure 
or toxicity plays a more important role in STa antigenicity, we selected STa(E8A) that retained some 
toxicity but had structure greatly altered, STa(T16Q) that had structure much maintained but toxicity 
lost, and STa(G17S) showing minimum change in either structure or toxicity to be genetically fused to 
LT(R192G), and used to immunize mice. Surprisingly, no significant differences were found among 
these  three  fusions  regarding  anti-STa  IgG  antibodies  elicitation.  Compared  to  the  fusion  of 
LT(R192G) and the native STa (LTR192G-STa), however, STa(T16Q) and STa(G17S) that had structure 
less  altered  exhibited  less  difference  in  eliciting  anti-STa  antibodies.  That  may  suggest  that  STa 
structure or epitope topology could influence more in anti-STa antigenicity, thus STa toxoids that had 
minimum structure alteration should be considered primarily as candidates for toxoid fusion construction. 
However, when porcine-type STa (pSTa) peptides pSTa(P12F) and pSTa(A13Q) were used in toxoid 
fusion  construction,  the  pLTR192G-pSTaP12F  stimulated  higher  titers  of  anti-STa  antibodies,  despite 
pSTa(A13Q) toxoid was structurally more similar to native pSTa [35]. Such contradiction could be 
caused by a lack of direct  comparison  to  the native  pSTa (used in  fusion  construction) from  our 
previous study. Considering that we only examined a small number of STa analogues, caution needs to 
be taken to draw conclusions based on observations from this study. Clearly, more studies will be Toxins 2011, 3  1159 
 
 
needed to better select STa toxoids for constructing LT and STa toxoid fusions, and perhaps a different 
animal model, such as a pig model, could help us to examine induced anti-STa antibodies in protection 
against STa-positive ETEC infection. In addition, further studies to construct a STa toxoid library, not 
just from the toxicity domain, but also the N-terminus, to select more STa peptide representatives for 
toxoid fusions, and to systematically examine these fusions for anti-STa antigenicity, would help us to 
identify optimum STa toxoids for ETEC vaccine development.  
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